Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Multiple Myeloma 1Acute Kidney Injury 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Plasma Exchange × Genitourinary × 1 year × Clear all
NCT07087860 2026-05-08

RECIPE-B1

Mayo Clinic

Phase 2 Recruiting
70 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Brigham and Women's Hospital

Recruiting
450 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡